scholarly journals Rectal indomethacin and diclofenac are equally efficient in preventing pancreatitis following endoscopic retrograde cholangiopancreatography in average‐risk patients

JGH Open ◽  
2021 ◽  
Vol 5 (10) ◽  
pp. 1119-1126
Author(s):  
Shuang Yu ◽  
Xumu Shen ◽  
Liang Li ◽  
Xiaofei Bi ◽  
Ping Chen ◽  
...  
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Average Risk ◽  
Endoscopic Retrograde ◽  
Risk Patients ◽  
Rectal Indomethacin

A Randomized Trial of Topical Epinephrine and Rectal Indomethacin for Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients

2019 ◽  
Vol 114 (2) ◽  
pp. 339-347 ◽  
Author(s):  
Ayesha Kamal ◽  
Venkata S. Akshintala ◽  
Rupjyoti Talukdar ◽  
Mahesh K. Goenka ◽  
Rakesh Kochhar ◽  
...  
Keyword(s):  
High Risk ◽  
Randomized Trial ◽  
Endoscopic Retrograde Cholangiopancreatography ◽  
Endoscopic Retrograde ◽  
High Risk Patients ◽  
Risk Patients ◽  
Rectal Indomethacin

Effect of Adding Intravenous Somatostatin to Rectal Indomethacin on Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High-risk Patients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Alireza Norouzi ◽  
Eshrat Ghasem Poori ◽  
Sajjad Kaabe ◽  
Zahra Norouzi ◽  
Ahmad Sohrabi ◽  
...  
Keyword(s):  
High Risk ◽  
Endoscopic Retrograde Cholangiopancreatography ◽  
Endoscopic Retrograde ◽  
High Risk Patients ◽  
Risk Patients ◽  
Rectal Indomethacin

scholarly journals Rectal Indomethacin Reduces Pancreatitis in High- and Low-Risk Patients Undergoing Endoscopic Retrograde Cholangiopancreatography

2016 ◽  
Vol 151 (2) ◽  
pp. 288-297.e4 ◽  
Author(s):  
Nikhil R. Thiruvengadam ◽  
Kimberly A. Forde ◽  
Gene K. Ma ◽  
Nuzhat Ahmad ◽  
Vinay Chandrasekhara ◽  
...  
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Low Risk ◽  
Endoscopic Retrograde ◽  
Risk Patients ◽  
Rectal Indomethacin

Tu1474 Risk Factor of Bleeding After Sphincterotomy During Endoscopic Retrograde Cholangiopancreatography in Average Risk Patients

2017 ◽  
Vol 85 (5) ◽  
pp. AB641-AB642
Author(s):  
Dong Wook Lee ◽  
Ho Gak Kim ◽  
Jimin Han ◽  
Sang Soo Bae ◽  
Jae Young Oh ◽  
...  
Keyword(s):  
Risk Factor ◽  
Endoscopic Retrograde Cholangiopancreatography ◽  
Average Risk ◽  
Endoscopic Retrograde ◽  
Risk Patients

scholarly journals Can topical epinephrine application to the papilla prevent pancreatitis after endoscopic retrograde cholangiopancreatography? Results from a double blind, multicentre, placebo controlled, randomised clinical trial

2021 ◽  
Vol 8 (1) ◽  
pp. e000562
Author(s):  
Adriana Fabiola Romano-Munive ◽  
J Jesus García-Correa ◽  
Luis F García-Contreras ◽  
José Ramírez-García ◽  
Luis Uscanga ◽  
...  
Keyword(s):  
Endoscopic Retrograde Cholangiopancreatography ◽  
Controlled Trial ◽  
Randomised Clinical Trial ◽  
Sterile Water ◽  
Endoscopic Retrograde ◽  
Double Blind ◽  
Registration Number ◽  
Baseline Characteristics ◽  
Randomised Controlled ◽  
Rectal Indomethacin

Background and study aimsPost-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a complication associated with important morbidity, occasional mortality and high costs. Preventive strategies are suboptimal as PEP continues to affect 4% to 9% of patients. Spraying epinephrine on the papilla may decrease oedema and prevent PEP. This study aimed to compare rectal indomethacin plus epinephrine (EI) versus rectal indomethacin plus sterile water (WI) for the prevention of PEP.Patients and methodsThis multicentre randomised controlled trial included patients aged >18 years with an indication for ERCP and naive major papilla. All patients received 100 mg of rectal indomethacin and 10 mL of sterile water or a 1:10 000 epinephrine dilution. Patients were asked about PEP symptoms via telephone 24 hours and 7 days after the procedure. The trial was stopped half way through after a new publication reported an increased incidence of PEP among patients receiving epinephrine.ResultsOf the 3602 patients deemed eligible, 3054 were excluded after screening. The remaining 548 patients were randomised to EI group (n=275) or WI group (n=273). The EI and WI groups had similar baseline characteristics. Patients in the EI group had a similar incidence of PEP to those in the WI group (3.6% (10/275) vs 5.12% (14/273), p=0.41). Pancreatic duct guidewire insertion was identified as a risk factor for PEP (OR 4.38, 95% CI (1.44 to 13.29), p=0.009).ConclusionSpraying epinephrine on the papilla was no more effective than rectal indomethacin alone for the prevention of PEP.Trial registration numberThis study was registered with ClinicalTrials.gov (NCT02959112).

Sign in / Sign up

Export Citation Format

Share Document